Earnings

Tectonic Clears TX2100 Phase 1b After Favorable Phase 1a Data

The Tip Desk · November 11, 2026 · 4 min read

Cash and cash equivalents were $234.7 million as of September 30, 2026, a balance the company said is expected to fund operations into the first quarter of 2029.

Tectonic Therapeutic, Inc. (TECX), a clinical-stage biotechnology company developing GPCR-targeted proteins and antibodies, reported a net loss of $21.3 million, or $1.08 a share, for the three months ended September 30, 2026, compared with a net loss of $19.0 million, or $1.02 a share, a year earlier.

The quarter’s defining development was not the loss but the clinical path it opened. In September 2026 the company announced favorable safety, tolerability and pharmacokinetic results from all six planned single-dose cohorts of TX2100 in the Phase 1a Part A trial in healthy adult volunteers. There were no serious adverse events or severe treatment-emergent adverse events at any dose, no clinically significant or dose-related changes in vital signs or laboratory assessments, and no anti-drug antibodies. Pharmacokinetics supported exploration of once-weekly and every-other-week subcutaneous dosing in planned trials.

In the immediately preceding quarter the company had only completed dosing of those six cohorts and said topline results were anticipated by the end of the third quarter. Those results now sit alongside two regulatory steps: the FDA granted TX2100 Fast Track designation for hereditary hemorrhagic telangiectasia in September 2026 and cleared the investigational new drug application in August 2026 for a planned Phase 1b trial.

President and Chief Executive Officer Alise Reicin said the Phase 1a findings, together with Fast Track designation and IND clearance, support plans to evaluate TX2100 in patients with HHT. The company said it plans to initiate an open-label Phase 1b trial in hematologic-support-dependent HHT by year-end 2026 and, in parallel, a placebo-controlled Phase 2 trial in moderate-to-severe HHT in early 2027. The TERRA Phase 1b trial is expected to dose about 20 patients subcutaneously once weekly for 24 weeks, with interim topline results expected by year-end 2027.

TX45, a long-acting Fc-relaxin fusion protein, also advanced. In October 2026 Tectonic dosed the first patient in the ALPINE Phase 2a trial in pulmonary hypertension associated with interstitial lung disease, an open-label, multinational, 16-week study in up to 25 patients. Dosing is to begin at 300 milligrams subcutaneously once monthly, with change from baseline in pulmonary vascular resistance at Week 16 as the primary endpoint. Interim topline results are expected in the second half of 2027.

The APEX Phase 2 trial of TX45 in pulmonary hypertension associated with heart failure with preserved ejection fraction remains the nearer readout. Enrollment completed in June 2026, and the independent data monitoring committee recommended in July 2026 that the trial continue without modification. Topline results are anticipated by the end of January 2027.

Research and development expenses were $17.4 million in the three months ended September 30, 2026, versus $16.9 million a year earlier. The company attributed the increase primarily to higher employee-related expenses, including stock-based compensation and headcount to support pipeline programs, partially offset by lower CDMO costs for TX2100 and lower clinical supply costs for TX45. General and administrative expenses were $6.0 million, versus $5.0 million a year earlier, which the company attributed primarily to higher employee-related expenses driven by non-cash stock-based compensation. Interest income was $2.1 million.

Cash and cash equivalents were $234.7 million as of September 30, 2026, compared with $227.1 million as of June 30, 2026, including about $22.3 million of net proceeds from an at-the-market offering in the three months ended September 30, 2026. Tectonic said that, based on current operating assumptions, the September 30 balance is expected to provide cash runway into the first quarter of 2029, including through anticipated Phase 2 topline readouts of TX45 in PH-HFpEF and PH-ILD and through anticipated clinical milestones in the TX2100 program.

The company said the TERRA Phase 1b trial of TX2100 in hematologic-support-dependent HHT is expected to initiate by year-end 2026, with interim topline results expected by year-end 2027, and that a parallel TIDAL Phase 2 trial in moderate-to-severe HHT is expected to initiate in early 2027.

More on TECX

September 28, 2026 QBook Stronger demand supports expansion as pricing diverges

Tectonic Therapeutic, Inc. — all coverage and financials